Bain Capital Life Sciences Investors LLC Invests $43.55 Million in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)

Bain Capital Life Sciences Investors LLC bought a new stake in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 7,470,214 shares of the company’s stock, valued at approximately $43,551,000. Olema Pharmaceuticals accounts for 5.1% of Bain Capital Life Sciences Investors LLC’s investment portfolio, making the stock its 7th biggest holding. Bain Capital Life Sciences Investors LLC owned approximately 13.04% of Olema Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently made changes to their positions in OLMA. KLP Kapitalforvaltning AS purchased a new stake in shares of Olema Pharmaceuticals in the 4th quarter worth about $30,000. Teacher Retirement System of Texas bought a new stake in Olema Pharmaceuticals during the fourth quarter worth about $60,000. Vontobel Holding Ltd. purchased a new stake in Olema Pharmaceuticals in the fourth quarter worth about $62,000. Fox Run Management L.L.C. bought a new position in shares of Olema Pharmaceuticals during the fourth quarter valued at approximately $80,000. Finally, SG Americas Securities LLC increased its stake in shares of Olema Pharmaceuticals by 33.8% during the fourth quarter. SG Americas Securities LLC now owns 17,475 shares of the company’s stock valued at $102,000 after purchasing an additional 4,419 shares in the last quarter. 91.78% of the stock is currently owned by institutional investors.

Olema Pharmaceuticals Price Performance

OLMA stock opened at $4.42 on Monday. The stock has a market capitalization of $302.03 million, a P/E ratio of -2.02 and a beta of 2.10. Olema Pharmaceuticals, Inc. has a 1-year low of $2.86 and a 1-year high of $16.62. The business has a fifty day moving average price of $4.20 and a 200-day moving average price of $7.00.

Olema Pharmaceuticals (NASDAQ:OLMA) last issued its earnings results on Tuesday, March 18th. The company reported ($0.51) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.12. As a group, analysts anticipate that Olema Pharmaceuticals, Inc. will post -2.33 earnings per share for the current year.

Analyst Ratings Changes

OLMA has been the subject of a number of analyst reports. JPMorgan Chase & Co. reduced their price objective on Olema Pharmaceuticals from $30.00 to $28.00 and set an “overweight” rating for the company in a research report on Friday, March 28th. HC Wainwright restated a “buy” rating and set a $30.00 price target on shares of Olema Pharmaceuticals in a report on Wednesday, March 19th. Finally, Oppenheimer reiterated an “outperform” rating and issued a $25.00 price target (down previously from $30.00) on shares of Olema Pharmaceuticals in a research note on Wednesday, March 19th.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.